A study assessing the association of cyclin D1 and fulvestrant response in patients with hormone receptor-positive (HR+) breast cancer

Trial Profile

A study assessing the association of cyclin D1 and fulvestrant response in patients with hormone receptor-positive (HR+) breast cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jul 2015

At a glance

  • Drugs Fulvestrant (Primary)
  • Indications Breast cancer
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 16 Jul 2015 New trial record
    • 02 Jun 2015 Primary endpoint has been met (Duration of response and its relation with cyclin D1 expression), according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top